ArticleADMET & DMPK2026
Zn-Ni metal-organic framework nanosheets@graphene oxide nanocomposite: A promising voltammetric platform for sensitive determination of doxorubicin.
Article in ADMET & DMPK, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Doxorubicin (DOX) serves as an anthracycline-based chemotherapy drug to treat multiple types of cancers and sarcomas, which include lung, breast, bladder, leukaemia, liver, head and neck cancers. Experimental approach: The electroanalysis of the trace level of DOX in this study was conducted using a Zn-Ni metal-organic framework nanosheets@graphene oxide nanocomposite (Zn-Ni MOF NSs@GO) after the modification of a screen-printed carbon electrode (Zn-Ni MOF NSs@GO/SPCE). Using chronoamperometry, cyclic voltammetry and differential pulse voltammetry, the electrochemical characteristics of the sensor as constructed for DOX measurement were examined. Key results: Consequently, the composite sensor demonstrated exceptional electrocatalytic performance in oxidizing DOX within a concentration range of 0.004 to 190.0 μM, with a detection limit of 0.001 μM. It was found that the Zn-Ni MOF NSs@GO/SPCE was effective at determining DOX in real samples, with good recovery values in the 97.1 to 102.0 % range. Conclusion: The designed sensor with cost-effective and good performance could be valuable for therapeutic drug monitoring and clinical diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.